At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Raleigh based CFO’ operating in the Biotechnology space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Karen Adams
CFO of Arrivo BioVentures LLC
Karen Adams has a 30 year career as a finance professional working with companies across a broad range of industries with the last 15 years focused on life sciences and technology. After starting her career as an Internal Auditor with International Paper Company, Inc., Karen Adams has held financial leadership positions with companies in software, professional services and biotechnology industries. Most recently, Karen Adams has been part of the management team, in the CFO role, responsible for the creation and sale of two companies (Addrenex Pharmaceuticals to Shionogi Pharma and Neuronex to Acorda Therapeutics) and Aerial BioPharma’s ADX-N05 asset sale to Jazz Pharmaceuticals. While Karen Adams life sciences experience has been primarily focused on early-stage, privately funded companies she was brought on as Assistant Controller at Millennium Pharmaceuticals, Inc. during its merger with COR Therapeutics – among the largest such mergers in the history of the biotech industry at that time. After Millennium Pharmaceuticals, Karen Adams went on to work with several early stage biotechnology ventures including Surface Logix, Inc., Compound Therapeutics, Inc., Galenea Corporation, BG Medicine, Inc., and Micell Technologies, Inc. Karen Adams contribution was concentrated on the creation of dynamic, integrated financial forecasting models as well as the implementation of core business structure. Karen Adams graduated from Boston College earning a BS in Management, majoring in Finance.
Follow Karen Adams:
About Arrivo BioVentures LLC, Emergo Therapeutics, KJA Associates, QuatroBio: Arrivo BioVentures is a pharmaceutical development company which focuses on identifying biologics and molecules to improve patient care.
Karen Adams
CFO of Arrivo BioVentures LLC
Karen Adams has a 30 year career as a finance professional working with companies across a broad range of industries with the last 15 years focused on life sciences and technology. After starting her career as an Internal Auditor with International Paper Company, Inc., Karen Adams has held financial leadership positions with companies in software, professional services and biotechnology industries. Most recently, Karen Adams has been part of the management team, in the CFO role, responsible for the creation and sale of two companies (Addrenex Pharmaceuticals to Shionogi Pharma and Neuronex to Acorda Therapeutics) and Aerial BioPharma’s ADX-N05 asset sale to Jazz Pharmaceuticals. While Karen Adams life sciences experience has been primarily focused on early-stage, privately funded companies she was brought on as Assistant Controller at Millennium Pharmaceuticals, Inc. during its merger with COR Therapeutics – among the largest such mergers in the history of the biotech industry at that time. After Millennium Pharmaceuticals, Karen Adams went on to work with several early stage biotechnology ventures including Surface Logix, Inc., Compound Therapeutics, Inc., Galenea Corporation, BG Medicine, Inc., and Micell Technologies, Inc. Karen Adams contribution was concentrated on the creation of dynamic, integrated financial forecasting models as well as the implementation of core business structure. Karen Adams graduated from Boston College earning a BS in Management, majoring in Finance.
Follow Karen Adams:
About Arrivo BioVentures LLC, Emergo Therapeutics, KJA Associates, QuatroBio: Arrivo BioVentures is a pharmaceutical development company which focuses on identifying biologics and molecules to improve patient care.
Adam Derbyshire
Chief Financial Officer of Salix Pharmaceuticals
Adam Derbyshire is the CFO at Salix Pharmaceuticals.
Follow Adam Derbyshire:
About Salix Pharmaceuticals: Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Matthew Navarro
Chief Financial Officer of Glympse Bio
Follow Matthew Navarro:
About Glympse Bio: Glympse Bio is a biotechnology company that transforms disease detection and predict treatment response.
Geremy Connor
Chief Financial Officer of Mako Medical Laboratories
Follow Geremy Connor:
About Mako Medical Laboratories: Mako Medical Laboratories is a hospital & health care company specializing in toxicology, genetics, and pathology testing solutions.
Stephen Hall
Executive Vice President, Chief Financial Officer of BG Medicine
Mr. Hall joined BG Medicine from Stemline Therapeutics, Inc., a publicly traded clinical stage biopharmaceutical company ,where he held the position of Vice President Finance, Treasurer, Principal Financial and Chief Accounting Officer and assisted in financings in excess of $100m. Prior to Stemline, Mr. Hall served as Chief Financial Officer at both life science and medical device companies, including Orthocon, Inc., Helicos BioSciences Corporation, TriPath Imaging, Inc., and Colorado MEDtech, Inc. Mr. Hall, a certified public accountant, began his professional career with Peat, Marwick, Mitchell & Co., in Chicago, IL. In addition to his experience as an operating CFO, he spent nearly 10 years in commercial banking. He received his AB degree from Harvard College and MBA from Stanford University Graduate School of Business.
Follow Stephen Hall:
About BG Medicine: BG Medicine is a life sciences company developing biomarker-based diagnostic tests for the cardiovascular sectors.
Katina Dorton
CFO of NodThera
Katina is a seasoned investment banker with over 20 years of Wall Street experience. She spent most of her career at Morgan Stanley, where she was a Managing Director in Corporate Finance. Previously, Katina was an attorney focused on M&A and securities matters. At Morgan Stanley, Katina worked in the Media/ Communications Group where she advised both large and emerging companies on capital raising and M&A. Katina spent two years as a senior banker in Morgan Stanley’s office in Frankfurt, Germany, where she worked with many European communications and media companies. Prior to Morgan Stanley, Katina practiced law in New York with Sullivan & Cromwell. After Morgan Stanley, Katina was Managing Director with Needham& Co, a boutique investment bank in New York. Most recently, Katina was a Senior Advisor to one of the predecessor firms of CoRise (DreamTigerEquities), and has worked with a number of entrepreneurial companies. Katina currently serves as a Senior Mentor in the CED’s Venture Mentoring Serivices, a mentoring service for start-up companies that is run in conjunction with MIT. Katina received an undergraduate degree in Economics from Duke University, a J.D. degree from the University of Virginia, and an MBA from George Washington University.
Follow Katina Dorton:
About NodThera: NodThera is a biotechnology company focused on the discovery and development of new treatments for diseases.